Clinical Data Spyre drug for inflammatory bowel disease shows promise in early study BioPharma DiveThe therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said.Clinical DataImmunology & InflammationRead full story pharminent April 13, 2026 (Last updated: April 14, 2026) BioPharma Dive The therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said. Clinical DataImmunology & InflammationRead full story Post navigation Previous: Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphomaNext: Alamar, Hemab, Kailera, and Seaport advance IPOs Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
